# A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

> **NCT02203513** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 111 (actual)

## Conditions studied

- Ovarian Cancer
- Breast Cancer
- Prostate Cancer

## Interventions

- **DRUG:** LY2606368

## Key facts

- **NCT ID:** NCT02203513
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-01-20
- **Primary completion:** 2021-08-27
- **Final completion:** 2021-08-27
- **Target enrollment:** 111 (ACTUAL)
- **Why stopped:** Eli Lilly prematurely terminated the study.
- **Last updated:** 2022-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02203513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02203513, "A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02203513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*